STAT+: Pharmalittle: We’re reading about a big Roche investment in the U.S., estrogen patch shortages, and more
Roche's Genentech will invest $750 million to double the size of its existing production facility in Oregon
As the work week winds down, many are already gearing up for weekend fun. Plans include spending time with mascots, reading, vacuuming, and seeking out the perfect iced coffee. A listening party is also on the agenda, featuring a mix of curated playlists.
Meanwhile, Roche has made a substantial investment in the United States, according to Pharmalot. However, the country is grappling with shortages of estrogen patches due to surging demand. The issue began last November when the FDA removed some of the most stringent safety warnings from hormone replacement therapy, leading to a surge in prescriptions.
The patches are notoriously difficult and time-consuming to manufacture compared to traditional pills, with limited production capacity exacerbating the shortage. As a result, many women are switching between brands and dosages in search of relief.
Pharma's woes extend beyond estrogen patches, with supply constraints persisting across the industry. A recent story in The Hill highlights these ongoing challenges.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
